Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Herr HW. Uncertainty, stage and outcome of invasive bladder cancer. J Urol 1994;152:401-2
   PubMed Web of Science ®Google Scholar
• Wolff EM, Chihara Y, Pan F, Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010;70:8169-78
   PubMed Web of Science ®Google Scholar
• Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980;46:1158-63
   PubMed Web of Science ®Google Scholar
• Bulbul MA, Chin JL, Huben RP, The effect of nitrofurantoin on bladder tumor cell lines: in vitro growth and implantation in the cauterized mouse bladder. J Urol 1985;134:1231-5
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9
   PubMed Web of Science ®Google Scholar
• Shang PF, Kwong J, Wang ZP, Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011;5-CD006885
   Google Scholar
• Shelley MD, Wilt TJ, Court J, Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485-90
   PubMed Web of Science ®Google Scholar
• Nepple KG, Lightfoot AJ, Rosevear HM, Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010;184:1915-19
   PubMed Web of Science ®Google Scholar
• Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002;127:20-6
   PubMed Web of Science ®Google Scholar
• Saint F, Patard JJ, Maille P, Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002;167:364-7
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG, Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604
   PubMed Web of Science ®Google Scholar
• Cheng CW, Chan PS, Chan LW, 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer. Int Braz J Urol 2005;31:204-11
   PubMedGoogle Scholar
• Porena M, Del Zingaro M, Lazzeri M, Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 2010;84:23-7
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:912-18
   PubMed Web of Science ®Google Scholar
• Colombo R, Lev A, Da Pozzo LF, A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 1995;153:959-63
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A, Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7:43-51
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Kirkali Z, Sylvester R, Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 2011;59:438-46
   PubMed Web of Science ®Google Scholar
• GuhaSarkar S, Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release 2010;148:147-59
   PubMed Web of Science ®Google Scholar
• Leakakos T, Ji C, Lawson G, Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 2003;51:445-50
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang CC, Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009;182:786-92
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Kikuchi E, Horinaga M, Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Hum Gene Ther 2011;22:1423-32
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90; quiz 435
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Valenti M, Verri C, Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 2011;12:871-9
   PubMed Web of Science ®Google Scholar
• Hall MC, Chang SS, Dalbagni G, Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-30
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008
   PubMed Web of Science ®Google Scholar
• Newling DW, Hetherington J, Sundaram SK, The use of valrubicin for the chemoresection of superficial bladder cancer – a marker lesion study. Eur Urol 2001;39:643-7
   PubMed Web of Science ®Google Scholar
• Pries AR, Cornelissen AJ, Sloot AA, Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 2009;5:e1000394
   PubMed Web of Science ®Google Scholar
• Roudier E, Perrin A. Considering the role of pyruvate in tumor cells during hypoxia. Biochim Biophys Acta 2009;1796:55-62
   PubMed Web of Science ®Google Scholar
• Rauth AM, Melo T, Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 1998;42:755-62
   PubMed Web of Science ®Google Scholar
• Roed H, Aabo K, Vindelov L, In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1989;25:1197-201
   PubMedGoogle Scholar
• Hendriks HR, Pizao PE, Berger DP, EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 1993;29A:897-906
   PubMed Web of Science ®Google Scholar
• Bailey SM, Lewis AD, Knox RJ, Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites. Biochem Pharmacol 1998;56:613-21
   PubMed Web of Science ®Google Scholar
• Fitzsimmons SA, Workman P, Grever M, Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-69
   PubMed Web of Science ®Google Scholar
• Plumb JA, Gerritsen M, Workman P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 1994;70:1136-43
   PubMed Web of Science ®Google Scholar
• Collard J, Matthew AM, Double JA, Bibby MC. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 1995;71:1199-203
   PubMed Web of Science ®Google Scholar
• Cummings J, Spanswick VJ, Gardiner J, Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9. Biochem Pharmacol 1998;55:253-60
   PubMed Web of Science ®Google Scholar
• Workman P, Binger M, Kooistra KL. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys 1992;22:713-16
   PubMed Web of Science ®Google Scholar
• Schellens JH, Planting AS, van Acker BA, Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst 1994;86:906-12
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Hanauske AR, Gamucci T, A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 1996;7:529-31
   PubMed Web of Science ®Google Scholar
• Dirix LY, Tonnesen F, Cassidy J, EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 1996;32A:2019-22
   PubMed Web of Science ®Google Scholar
• Phillips RM, Loadman PM, Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 1998;77:2112-19
   PubMed Web of Science ®Google Scholar
• Choudry GA, Stewart PA, Double JA, A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer 2001;85:1137-46
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Verhaegh G, Jansen CF, Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 2005;173:1375-80
   PubMed Web of Science ®Google Scholar
• Vainchtein LD, Rosing H, Mirejovsky D, Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer. J Pharm Biomed Anal 2007;43:285-92
   PubMed Web of Science ®Google Scholar
• Puri R, Palit V, Loadman PM, Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol 2006;176:1344-8
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Moonen PM, Cornel EB, Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 2006;176:1349-53; discussion 53
   PubMed Web of Science ®Google Scholar
• Jain A, Phillips RM, Scally AJ, Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 2009;73:1083-6
   PubMed Web of Science ®Google Scholar
• Hendricksen K, van der Heijden AG, Cornel EB, Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 2009;27:337-42
   PubMed Web of Science ®Google Scholar
• Chin JL, Kadhim SA, Batislam E, Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 1996;156:1189-93
   PubMed Web of Science ®Google Scholar
• Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol 2009;181:1040-5
   PubMed Web of Science ®Google Scholar
• (Ed.ˆ(Eds) (U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894)
   Google Scholar